Skip to main content

FeNO National Programme Impact Report

A new report is showcasing the impact of a national AHSN Network programme to improve access to FeNO testing for asthma diagnosis.

Fractional exhaled Nitric Oxide (FeNO) tests are simple, non-invasive tests to support the diagnosis of asthma.

During the two-year programme an estimated 58,000 new asthmatics received a faster, more accurate diagnosis through the use of FeNO testing with an additional 1,200 devices entering use in primary care in England.

The AHSN Network delivered the programme as part of the NHS England Accelerated Access Collaborative Rapid Uptake Products Programme designed to improve access to new treatments and technologies.